| dc.contributor.author | Ozdogan, Huri | |
| dc.contributor.author | Esatoglu, Sinem Nihal | |
| dc.contributor.author | Hatemi, Gülen | |
| dc.contributor.author | Tascilar, Koray | |
| dc.contributor.author | Ugurlu, Serdal | |
| dc.contributor.author | Gokturk, Aycan | |
| dc.date.accessioned | 2021-03-06T21:05:00Z | |
| dc.date.available | 2021-03-06T21:05:00Z | |
| dc.date.issued | 2017 | |
| dc.identifier.citation | Esatoglu S. N. , Hatemi G., Ugurlu S., Gokturk A., Tascilar K., Ozdogan H., "Long-term follow-up of secondary amyloidosis patients treated with tumor necrosis factor inhibitor therapy A STROBE-compliant observational study", MEDICINE, cilt.96, 2017 | |
| dc.identifier.issn | 0025-7974 | |
| dc.identifier.other | av_fd2b6211-a806-48b7-86f7-b9cabccc3be5 | |
| dc.identifier.other | vv_1032021 | |
| dc.identifier.uri | http://hdl.handle.net/20.500.12627/165637 | |
| dc.identifier.uri | https://doi.org/10.1097/md.0000000000007859 | |
| dc.description.abstract | There are no treatment modalities, which were proven to prevent the deposition of amyloid, proteinuria, and loss of renal function due to amyloidosis. Anti-tumor necrosis factor agents (anti-TNFs) were shown to decrease the production of serum amyloid A protein. We aimed to evaluate the long-term efficacy and safety of anti-TNFs in secondary (AA) amyloidosis patients treated in a single center. | |
| dc.language.iso | eng | |
| dc.subject | TIP, GENEL & İÇECEK | |
| dc.subject | Klinik Tıp | |
| dc.subject | Klinik Tıp (MED) | |
| dc.subject | Sağlık Bilimleri | |
| dc.subject | Tıp | |
| dc.subject | Temel Tıp Bilimleri | |
| dc.title | Long-term follow-up of secondary amyloidosis patients treated with tumor necrosis factor inhibitor therapy A STROBE-compliant observational study | |
| dc.type | Makale | |
| dc.relation.journal | MEDICINE | |
| dc.contributor.department | İstanbul Üniversitesi , , | |
| dc.identifier.volume | 96 | |
| dc.identifier.issue | 34 | |
| dc.contributor.firstauthorID | 67253 | |
